Krystal Biotech Stock Performance
| KRYS Stock | USD 187.15 1.46 0.77% |
On a scale of 0 to 100, Krystal Biotech holds a performance score of 8. The company secures a Beta (Market Risk) of 0.53, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Krystal Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Krystal Biotech is expected to be smaller as well. Please check Krystal Biotech's treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to make a quick decision on whether Krystal Biotech's current price movements will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Krystal Biotech unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 358.3 M |
Krystal |
Krystal Biotech Relative Risk vs. Return Landscape
If you would invest 16,083 in Krystal Biotech on December 22, 2024 and sell it today you would earn a total of 2,632 from holding Krystal Biotech or generate 16.37% return on investment over 90 days. Krystal Biotech is currently generating 0.2862% in daily expected returns and assumes 2.6327% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Krystal, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Krystal Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Krystal Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Krystal Biotech, and traders can use it to determine the average amount a Krystal Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1087
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KRYS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.63 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Krystal Biotech is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Krystal Biotech by adding it to a well-diversified portfolio.
Krystal Biotech Fundamentals Growth
Krystal Stock prices reflect investors' perceptions of the future prospects and financial health of Krystal Biotech, and Krystal Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Krystal Stock performance.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0688 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 4.84 B | ||||
| Shares Outstanding | 28.81 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 5.74 X | ||||
| Price To Sales | 18.70 X | ||||
| Revenue | 290.51 M | ||||
| EBITDA | 109.91 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 7.26 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 32.87 X | ||||
| Cash Flow From Operations | 123.42 M | ||||
| Earnings Per Share | 3.00 X | ||||
| Total Asset | 1.06 B | ||||
| Retained Earnings | (180.67 M) | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
About Krystal Biotech Performance
Assessing Krystal Biotech's fundamental ratios provides investors with valuable insights into Krystal Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Krystal Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.Things to note about Krystal Biotech performance evaluation
Checking the ongoing alerts about Krystal Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Krystal Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 88.0% of the company shares are owned by institutional investors |
- Analyzing Krystal Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Krystal Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Krystal Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Krystal Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Krystal Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Krystal Biotech's stock. These opinions can provide insight into Krystal Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.